Cerevel Therapeutics (CERE) PT Raised to $50 at Stifel
Tweet Send to a Friend
Stifel analyst Paul Matteis raised the price target on Cerevel Therapeutics (NASDAQ: CERE) to $50.00 (from $33.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
